Moreover, GLP-1 could be involved in mechanisms of growth and expansion of IECs, as the loss of GLP-1Rs on IELs has been associated with shorter and smaller intestines in mice (59, 63, 64)
The START-SYNERGY trial will enroll ~180 patients across 9 countries, including the US, South Africa, Serbia, Poland, Czech Republic, Spain, Netherlands, Bulgaria, and Hungary, evaluating ELV001 as an oral add-on therapy to standard care
no significant differences were seen between user and non-user groups, with 33% of both having escalations, and slightly more of the non-users having de-escalations (16% vs 7%)
The dose is increased to 5 milligrams after four weeks
This is a common and legal practice when a provider believes it is appropriate for a patients health needs
Clothes that fit tightly around your waist put pressure on your abdomen and the lower esophageal sphincter